← Back to Screener
Damora Therapeutics, Inc. Common Stock (DMRA)
Price$24.85
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (4W)-6.86%
VGM Score30.92
Market Capitalization$1.53B
All Metrics
Book Value / Share (Quarterly)$8.48
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.41
Price vs S&P 500 (YTD)-14.18%
EPS (TTM)$-141.43
10-Day Avg Trading Volume0.35M
EPS Excl Extra (TTM)$-141.43
EPS (Annual)$-153.95
ROI (Annual)-87.29%
Cash / Share (Quarterly)$8.84
ROA (Last FY)-80.54%
EBITD / Share (TTM)$-25.11
ROE (5Y Avg)-97.04%
Cash Flow / Share (Annual)$-4.21
P/B Ratio2.99x
P/B Ratio (Quarterly)3.05x
Net Income / Employee (Annual)$-29,977,000
Net Interest Coverage (TTM)-145.71x
ROA (TTM)-115.66%
EPS Incl Extra (Annual)$-153.95
Current Ratio (Annual)12.98x
Quick Ratio (Quarterly)22.43x
3-Month Avg Trading Volume0.31M
Revenue / Employee (TTM)$0
52-Week High$29.22
EPS Excl Extra (Annual)$-153.95
Quick Ratio (Annual)12.91x
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)22.48x
Enterprise Value$998.54M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$161.29
Net Income / Employee (TTM)$-33,889,000
ROE (Last FY)-87.29%
Net Interest Coverage (Annual)-151.27x
EPS Basic Excl Extra (Annual)$-153.95
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-141.43
Receivables Turnover (Annual)0.00x
ROI (TTM)-123.08%
Revenue / Share (Annual)$0.00
Year-to-Date Return-2.47%
5-Day Price Return-1.66%
EPS Normalized (Annual)$-153.95
ROA (5Y Avg)-86.51%
Month-to-Date Return-3.04%
EBITD / Share (Annual)$-154.69
ROI (5Y Avg)-97.04%
EPS Basic Excl Extra (TTM)$-141.43
Beta-5.26x
Revenue / Share (TTM)$0.00
ROE (TTM)-123.08%
52-Week Low$16.50
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.62est. -0.40
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.38
4.30
4.27
4.25
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DMRADamora Therapeutics, Inc. Common Stock | — | — | D | $24.85 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Damora Therapeutics develops biologics for calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant unmet medical need for disease-modifying treatments. The company's pipeline includes DMR-001, DMR-002, DMR-003, and GB3226, designed to provide broad mutation coverage in hematologic disorders.